SARS-CoV-2 Seroprevalence and Antibody Kinetics Among Health Care Workers in a Spanish Hospital After 3 Months of Follow-up.
COVID-19
SARS-CoV-2
antibodies
health care workers
kinetics
longitudinal cohort
seroprevalence
Journal
The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675
Informations de publication
Date de publication:
04 01 2021
04 01 2021
Historique:
received:
24
08
2020
accepted:
29
10
2020
pubmed:
12
11
2020
medline:
16
1
2021
entrez:
11
11
2020
Statut:
ppublish
Résumé
At the COVID-19 spring 2020 pandemic peak in Spain, prevalence of SARS-CoV-2 infection in a cohort of 578 randomly selected health care workers (HCWs) from Hospital Clínic de Barcelona was 11.2%. A follow-up survey 1 month later (April-May 2020) measured infection by rRT-PCR and IgM, IgA, and IgG to the receptor-binding domain of the spike protein by Luminex. Antibody kinetics, including IgG subclasses, was assessed until month 3. At month 1, the prevalence of infection measured by rRT-PCR and serology was 14.9% (84/565) and seroprevalence 14.5% (82/565). We found 25 (5%) new infections in 501 participants without previous evidence of infection. IgM, IgG, and IgA levels declined in 3 months (antibody decay rates 0.15 [95% CI, .11-.19], 0.66 [95% CI, .54-.82], and 0.12 [95% CI, .09-.16], respectively), and 68.33% of HCWs had seroreverted for IgM, 3.08% for IgG, and 24.29% for IgA. The most frequent subclass responses were IgG1 (highest levels) and IgG2, followed by IgG3, and only IgA1 but no IgA2 was detected. Continuous and improved surveillance of SARS-CoV-2 infections in HCWs remains critical, particularly in high-risk groups. The observed fast decay of IgA and IgM levels has implications for seroprevalence studies using these isotypes.
Sections du résumé
BACKGROUND
At the COVID-19 spring 2020 pandemic peak in Spain, prevalence of SARS-CoV-2 infection in a cohort of 578 randomly selected health care workers (HCWs) from Hospital Clínic de Barcelona was 11.2%.
METHODS
A follow-up survey 1 month later (April-May 2020) measured infection by rRT-PCR and IgM, IgA, and IgG to the receptor-binding domain of the spike protein by Luminex. Antibody kinetics, including IgG subclasses, was assessed until month 3.
RESULTS
At month 1, the prevalence of infection measured by rRT-PCR and serology was 14.9% (84/565) and seroprevalence 14.5% (82/565). We found 25 (5%) new infections in 501 participants without previous evidence of infection. IgM, IgG, and IgA levels declined in 3 months (antibody decay rates 0.15 [95% CI, .11-.19], 0.66 [95% CI, .54-.82], and 0.12 [95% CI, .09-.16], respectively), and 68.33% of HCWs had seroreverted for IgM, 3.08% for IgG, and 24.29% for IgA. The most frequent subclass responses were IgG1 (highest levels) and IgG2, followed by IgG3, and only IgA1 but no IgA2 was detected.
CONCLUSIONS
Continuous and improved surveillance of SARS-CoV-2 infections in HCWs remains critical, particularly in high-risk groups. The observed fast decay of IgA and IgM levels has implications for seroprevalence studies using these isotypes.
Identifiants
pubmed: 33175145
pii: 5974123
doi: 10.1093/infdis/jiaa696
pmc: PMC7717341
doi:
Substances chimiques
Antibodies, Viral
0
Immunoglobulin A
0
Immunoglobulin G
0
Immunoglobulin M
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
62-71Subventions
Organisme : NIAID NIH HHS
ID : HHSN272201400008C
Pays : United States
Informations de copyright
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
Références
Front Immunol. 2013 Aug 09;4:235
pubmed: 23950757
Nat Med. 2020 Jul;26(7):1033-1036
pubmed: 32398876
J Clin Invest. 1964 Jun;43:1036-48
pubmed: 14170104
Lancet. 2020 Jul 25;396(10246):e6-e7
pubmed: 32653078
JAMA Netw Open. 2020 May 1;3(5):e209666
pubmed: 32437575
J Clin Microbiol. 2021 Jan 21;59(2):
pubmed: 33127841
JAMA Netw Open. 2020 May 1;3(5):e209673
pubmed: 32437576
Clin Exp Immunol. 1973 Apr;13(4):521-8
pubmed: 4717094
Cell Rep Med. 2020 Jun 23;1(3):100040
pubmed: 32835303
Nat Commun. 2020 Jul 8;11(1):3500
pubmed: 32641730
Nat Med. 2020 Aug;26(8):1200-1204
pubmed: 32555424
Cell. 2020 Jun 25;181(7):1489-1501.e15
pubmed: 32473127
JAMA. 2020 Sep 17;:
pubmed: 32940635
J Clin Invest. 1970 Apr;49(4):673-80
pubmed: 5443170
J Hosp Infect. 2020 Oct;106(2):357-363
pubmed: 32702465
Ann Intern Med. 2020 Sep 1;173(5):362-367
pubmed: 32491919
Curr Protoc Microbiol. 2020 Jun;57(1):e100
pubmed: 32302069
Elife. 2020 May 11;9:
pubmed: 32392129
Cell Mol Immunol. 2020 Jul;17(7):773-775
pubmed: 32467617
Nat Commun. 2020 Sep 17;11(1):4704
pubmed: 32943637
Front Immunol. 2020 May 15;11:1049
pubmed: 32574261
Lancet Infect Dis. 2021 Apr;21(4):e67
pubmed: 32628906
N Engl J Med. 2020 Sep 10;383(11):1085-1087
pubmed: 32706954
Ann Intern Med. 2020 Jul 21;173(2):120-136
pubmed: 32369541
Nat Rev Immunol. 2020 Jul;20(7):392-394
pubmed: 32514035
Lancet. 2020 Aug 22;396(10250):535-544
pubmed: 32645347